Advertisement

Topics

Latest "Galectin Therapeutics" News Stories

19:13 EST 22nd February 2017 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 7,700+

Extremely Relevant

Galectin Therapeutics Inc. (GALT) Stock Rating Lowered by Zacks Investment Research

According to Zacks, "Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function.


BRIEF-Galectin Therapeutics Q3 loss per share $0.19

* Galectin Therapeutics Inc- on track for reporting of top-line results in december of 2017 for nash-cx trial

Galectin Therapeutics raises $375k in private convertible share sale; later sells additional $1mm

In an initial closing, Galectin Therapeutics Inc. (carbohydrate-based therapies for fibrotic liver disease and cancer based on understanding of galectin proteins) sold 375k shares (of a potential 1.5mm shares) of Series B-3 convertible preferred stock and warrants to purchase 104k common shares to 10X Fund for gross proceeds of $375k.


BRIEF-Galectin therapeutics announces $4 mln in new equity financing

* Galectin Therapeutics announces $4 million in new equity financings

BRIEF-Richard Uihlein reports 7.89 pct stake in Galectin Therapeutics

* Richard Uihlein reports 7.89 percent stake in Galectin Therapeutics Inc as of Dec 22 - SEC filing Source text: (http://bit.ly/2jMCBRA) Further company coverage:

Galectin tanks as NASH drug candidate fails in study of patients with advanced fibrosis

Galectin Therapeutics has reported disappointing results from a mid-stage study of its candidate compound…

Galectin Therapeutics raises $3mm in common stock private placement

Galectin Therapeutics Inc. (carbohydrate-based therapies for fibrotic liver disease and cancer based on understanding of galectin proteins) raised $3mm through the sale of 2.8mm common shares and 2.1mm common stock purchase warrants (strike price of $5). The offering was sold in units with each unit consisting of one common share and one seven-year warrant to purchase 0.75 of a common share at a ...

BRIEF-Galectin Therapeutics announces positive new psoriasis and atopic dermatitis clinical data

* Galectin Therapeutics announces positive new psoriasis and atopic dermatitis clinical data, seeking strategic partnerships for therapy of severe skin diseases Source text for Eikon: Further company coverage:

Galectin Therapeutics, Inc. formerly ProPharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350

Project Synopsis:Datamonitor's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.Project Description:Datamonitors' Galectin Therapeutics, Inc. formerly ProPharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Allianc...

Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2

The Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com NORCROSS, Ga., Jan. 30, 2017 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D, president, chief executive officer a...

Relevant

RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways

BBI Solutions launches new range of antibodies for Galectin-3 biomarker

BBI Solutions has announced the launch of a range of antibodies for the biomarker Galectin-3. The antibodies complement BBI’s Galectin-3 antigen, which was also launched earlier this year.

A Major Catalyst Awaits Galectin Therapeutics Next Week

Galectin Therapeutics (GALT) Investor Presentation - Slideshow

Galectin Therapeutics Presents At The MicroCap Plus Conference - Slide Show

Galectin plunges after miss in exploratory NASH trial

Shares in the biotech nearly halved in value Wednesday, as investors soured on the potential of Galectin's lead drug after it failed to hit its goal in a Phase 2a study. 

BRIEF-Galectin says announces top-line data from exploratory phase 2A pilot trial (NASH-FX)

* Galectin therapeutics announces top-line data from exploratory phase 2a pilot trial (nash-fx) with gr-md-02 in nash patients with advanced fibrosis

Galectin Therapeutics Presentation Now Available for On-Demand Viewing

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation NORCROSS, Ga., Feb. 6, 2017 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the February 2nd presentation from Peter G. Traber, M.D, President, C...

BRIEF-Galectin Therapeutics has says can cover expenditures through 2017 - SEC filing

* Has generated sufficient financing to cover currently planned expenditures through 2017 - sec filing

Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) ...

Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled Closed private placement financing for $1.5 million Conference call to be held today at 5:30 p.m. (Eastern Time) NORCOSS, Ga., Sept. 27, 2016 (GLOBE NEWSWIRE) Read more...

Galectin 1 14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 o

Galectin 1 14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1 Pipeline Review, H2 2016SummaryGlobal Markets Direct's, Galectin 1 14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside ...

Galectin Therapeutics Inc GALT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryGalectin Therapeutics Inc Galectin Therapeutics, formerly ProPharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GRMD02 and GMCT01. Its GRMD02 is a drug candidate used for treating fibrotic liver disease. Its GMCT01 is a vaccine used to treat patients with advanced melanoma, a...

Galectin suffers blow as NASH trial fails

As big pharma races to develop a treatment for the liver disease non-alcoholic steatohepatitis (NASH), biotech Galectin suffered a blow as its potential treatment failed in a mid-stage clinical trial. Galectin said its phase 2a NASH-FX trial evaluating GR-MD-02 in 30 NASH patients with advanced fibrosis failed to meet its endpoint. The exploratory four month long randomised study did not meet it...

Bidding War For Galectin Inhibitors May Heat Up With GTCBio Conference

Galectin Therapeutics, Inc. GALT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryGalectin Therapeutics, Inc. Galectin Therapeutics is a biotechnology company that offers therapies. The company discovers, develops and commercializes therapies for fibrotic disease and cancer. Its products include GRMD02 and GMCT01. The company's GRMD02 is a drug candidate used in the treatment of fibrotic liver disease. Galectin Therapeutics's GMCT01 is a vaccine used to treat patients wi...


Quick Search
Advertisement
 

News Quicklinks